Clinical Trial Update: A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for GI-108, a bispecific anti-CD73-IL-2v fusion protein, being studied as monotherapy in advanced or metastatic solid tumors; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Renal Cell Carcinoma

Drugs mentioned

• GI-108 (GI-108)

Snippet

Sponsor: GI Innovation, Inc. | Conditions: Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1, Phase 2 | Status: RECRUITING